MHRA Publishes Updated Guidance on Clinical Investigations for Medical Devices

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has released an updated version of its guidance document titled Clinical Investigations of Medical Devices – Guidance for Manufacturers. This April 2025 edition provides detailed information for manufacturers planning to conduct clinical investigations in the UK.

Key updates in this version include:

  • Clarification of Terminology: The document now uses ‘participants’ as the preferred term, replacing previous terminology to enhance clarity and inclusivity.
  • Validation Terms and Regulatory Basis: There is a clearer explanation of terms used in the validation process, aligning them more closely with their regulatory foundations.
  • Readability Enhancements: Minor adjustments have been made throughout the document to improve overall readability and comprehension.

The guidance outlines the requirements for notifying the MHRA about clinical investigations, detailing the processes for both Great Britain and Northern Ireland. It emphasises the differing regulatory frameworks: UK MDR 2002 applies in Great Britain, while EU MDR and IVDR regulations continue to apply in Northern Ireland under the Northern Ireland Protocol.

Manufacturers are advised to consult this updated guidance to ensure compliance with the latest regulatory requirements when planning clinical investigations in the UK.

The full guidance document is available here: Clinical Investigations of Medical Devices – Guidance for Manufacturers (April 2025)